drugset / Trial / NCT02031419
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma
Timeline
- Start
- 2013-12-18
- Primary completion
- 2023-12-12
- Completion
- 2023-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avadomide | Other / unclassified | 2 mg | Oral |
| Subject | Avadomide | Other / unclassified | 3 mg | Oral |
| Subject | ONATASERTIB | Small molecule | 20 mg | Oral |
| Subject | ONATASERTIB | Small molecule | 30 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Spebrutinib | Small molecule | 500 mg | Oral |